Harvard College

Genetics Institute, Inc.

Other

The Brigham and Women's Hospital, Inc.

The General Hospital Corporation

Children's Medical Center Corporation

Curis, Inc.

Genetics, Institute Institute, Llc.

Janssen Biotech, Inc.

Genetics Institute, LLC Et Al.

Douglas A Melton

Jeffrey R Millman

Mads Gurtler

Felicia J Pagliuca

Michael Saris Segel

Quinn P Peterson

John Martin Wozney

Neil M Wolfman

Anthony J Celeste

Vicki A Rosen

Shuibing C Chen

Stuart L Schreiber

Richard Theodore Lee

Qiao Zhou

Tod M Woolf

Alireza Rezania

Gerald H Thomsen

Lee L Rubin

Weiping Tang

Benjamin Fryer

Malgorzata Borowiak

Julia Lamenzo Fox

Ali Hemmati-Brivanlou

Lance Davidow

Ping Jin

Lee F Peng

Jonathan M Graff

Mads Gürtler

Kelvin Lam

Rene Maehr

Ornella Barrandon

Tommaso Poggioli

Peter S Klein

Julia Lamenzo

Jessica Garbern

Aharon Helman

Edwin Rosado-Olivieri

Jose Rivera-Feliciano

Sinisa Hrvatin

Edwin Antonio Rosado-Olivieri

Michael Saris Segal

Gerald H Thomson

Vicky A Rosen

Disclosed herein are methods for generating SC-β cells, and isolated populations of SC-β cells for use in various applications, such as cell therapy.

Methods for generating stem cell-derived β cells and methods of use thereof

A previously uncharacterized gene and gene product are disclosed herein that increase blood glucose clearance independent of insulin. Also described is a methodology for enriching for mRNAs transcribing excreted and membrane bound proteins as well as a non-human animal expressing a labeled SEC61b protein.

Methods and compositions for treating diabetes, and methods for enriching MRNA coding for secreted proteins

Disclosed herein are methods, compositions, kits, and agents useful for inducing β cell maturation, and isolated populations of SC-β cells for use in various applications, such as cell therapy.

SC-beta cells and compositions and methods for generating the same

Disclosed herein are a means to prevent and/or ameliorate age, disease and obesity associated metabolic diseases, such as diabetes and impaired glucose tolerance. Also disclosed are compositions and methods that relate to the findings that GDF11 prevents weight gain, improves glucose tolerance and reduces hepatosteatosis in aged mice administered a high fat diet. In particular, the methods and compositions described herein relate to increasing the level of GDF11 in a subject, thereby treating or preventing the development of obesity in the subject, reducing the metabolic consequences of obesity and improving the subject's metabolic health.

Method of treating or inhibiting glucose intolerance

Disclosed herein are methods for generating mature cardiomyocytes and compositions including mature cardiomyocytes. Also disclosed herein are methods for enhancing maturation of quiescent cardiomyocytes and compositions including mature quiescent cardiomyocytes.

Cardiomyocytes and compositions and methods for producing the same

Disclosed herein are methods, compositions, kits, and agents useful for inducing &#x3b2; cell maturation, and isolated populations of SC-&#x3b2; cells for use in various applications, such as cell therapy.

Disclosed herein are methods for generating SC-&#x3b2; cells, and isolated populations of SC-&#x3b2; cells for use in various applications, such as cell therapy.

Methods for generating stem cell-derived beta cells and methods of use thereof

The present invention provides methods of reprogramming cells, for example, directly reprogramming a somatic cell of a first cell type into a somatic cell of a second cell type, are described herein. In particular, the present invention generally relates to methods for reprogramming a cell of an endoderm origin to a cell having pancreatic &#x3b2;-cell characteristics. The present invention also relates to an isolated population comprising reprogrammed cells, compositions and their use in the treatment of diabetes mellitus. In particular, the present invention relates to reprogramming a cell of an endoderm origin to a cell having pancreatic &#x3b2;-cell characteristics by increasing the protein expression of at least one transcription factor selected from Pdx1, Ngn3 or MafA in the cell of endoderm origin to reprogram the cell of an endoderm cell to a cell which exhibits at least one or at least two characteristics of an endogenous pancreatic &#x3b2;-cell.

Methods of reprogramming cells

Disclosed herein are methods for generating SC-&#x3b2; cells using chemically defined, completely serum free media, and isolated populations of SC-&#x3b2; cells for use in various applications, such as cell therapy.

Serum-free in vitro directed differentiation protocol for generating stem cell-derived beta cells and uses thereof

Growing community of inventors

Lexington, MA, United States of America

Douglas A Melton